x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012881
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human TBC1D7 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TBC1D7 |
| UniProt No. | Q9P0N9 |
| Gene ID | 107080638 |
| Gene Description | TBC1 domain family member 7 belongs to a family of TBC containing proteins that function as GTPase-activating proteins. TBC1D7 was initially identified as a novel binding protein within the TSC1-TSC2 complex, where it was thought to associate with TSC1. Additional research indicates that TBC1D7 is a third subunit of the TSC1-TSC2 complex that possesses Rheb-GAP activity and signals upstream of mTORC1. Knockdown of TBC1D7 limits the association between TSC1 and TSC2, resulting in reduced Rheb-GAP activity and increased mTORC1 signaling. Mutations in the corresponding TBC1D7 gene result in increased mTORC1 signaling, delayed autophagy, and are associated with intellectual disability and macrocrania. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
